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Summary 
 
15-hydroxyprostaglandin dehydrogenase (HPGD) plays a key role in prostaglandins (PGs) 
catabolism. Its expression and activity appear to be regulated by progesterone (P4). We 
investigated the HPGD mRNA-expression and protein localization in placentomes and 
interplacental uterine sites throughout gestation (Study I), and after fetal membranes retention 
(RFM) compared with normally delivered fetal membranes (DFM) (Study II). Furthermore, 
we analyzed the influence of aglepristone (AP), dexamethasone (GC) or cloprostenol (CP), on 
HPGD expression in bovine placentomes (Study III). Tissues from late gestation (D272) and 
at normal term (NT) served as controls. HPGD was highest in all sites at the beginning of 
pregnancy and at (NT). Following induced parturition HPGD was lower after (AP) and (GC) 
compared with (NT), and was similar in RFM and DFM. Placentomes stained primarily in 
fetal compartments; interplacentomal signals were observed in glandular and luminal 
epithelium. Results indicate that HPGD may play a role during establishment and termination 
of gestation. 
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Zusammenfassung 
 
Die 15-Hydroxyprostaglandin-Dehydrogenase (HPGD) spielt eine zentrale Rolle beim Abbau 
von Prostaglandinen (PGs). Ihre Expression und Aktivität scheinen durch Progesteron (P4) 
reguliert zu werden. Wir untersuchten die HPGD-mRNA-Expression und -Protein-
Lokalisation in Plazentomen und im interplazentomären Uterusgewebe während der 
Trächtigkeit (Studie I) sowie nach einer Retentio secundinarum (RFM) und im Vergleich zu 
normal abgegangenen fetalen Hüllen (DFM) (Studie II). Darüber hinaus untersuchten wir den 
Einfluss von Aglepriston (AP), Dexamethason (GC) oder Cloprostenol (CP) auf die HPGD-
mRNA-Expression in bovinen Plazentomen (Studie III). Als Kontrollen dienten Gewebe aus 
der späten Trächtigkeit (D272) und nach physiologischen Geburten (NT). Die HPGD-mRNA-
Expression in Plazentomen und interplazentomären Uterusgeweben war zu Beginn der 
Trächtigkeit und nach normaler Geburt (NT) am höchsten. Nach induzierter Geburt mittels 
AP- und GC-Applikation war die HPGD-mRNA-Expression niedriger als im Vergleich zu 
(NT) und vergleichbar zu der bei RFM- und DFM-Tieren. Plazentome waren vor allem in 
fetalen Kompartimenten immunopositiv; interplazentomäre Signale wurden im Drüsen- und 
Oberflächenepithel beobachtet. Die Ergebnisse lassen vermuten, dass die HPGD vor allem 
eine Rolle bei der Etablierung und Beendigung der Trächtigkeit spielen dürfte. 
 
 
  
Prostaglandins & other Lipid Mediators 128–129 (2017) 17–26
Contents lists  available at ScienceDirect
Prostaglandins and  Other  Lipid  Mediators
Uterine  and  placental  expression  of HPGD  in  cows  during  pregnancy
and  release  of  fetal membranes
Jessica  von  Hof a, Nele Sprekeler a, Gerhard  Schulerb, Alois  Boos a,1,
Mariusz  P.  Kowalewski a,∗,1
a Institute of Veterinary Anatomy, Vetsuisse Faculty, University of  Zurich, Winterthurerstrasse 260, 8057 Zurich, Switzerland
b Clinic for Obstetrics, Gynecology and Andrology of  Large and Small Animals, Faculty of Veterinary Medicine, Justus-Liebig-University Giessen, 35392
Giessen, Germany
a  r  t  i  c  l  e  i n f  o
Article history:
Received 26 September 2016
Received in revised form
15 December 2016
Accepted 29 December 2016
Available online 30  December 2016
Keywords:
HPGD
Cattle
Bovine
Placenta
Uterus
Gestation
Retained fetal membranes
a  b  s t  r  a c  t
15-Hydroxyprostaglandin  dehydrogenase (HPGD)  plays a key  role  in  prostaglandins (PGs) catabolism.  Its
expression  and activity  appear to  be  regulated  by  progesterone  (P4).  We investigated  the HPGD mRNA-
expression  and  protein  localization  in placentomes  and  interplacental uterine  sites throughout  gestation
(Study I),  and  after  fetal  membranes retention  (RFM)  compared  with  normally delivered fetal  membranes
(DFM) (Study II). Furthermore, we analyzed  the  influence of aglepristone  (AP),  dexamethasone  (GC) or
cloprostenol  (CP),  on HPGD expression  in bovine placentomes  (Study  III). Tissues  from  late gestation
(D272)  and at normal  term (NT) served as  controls.  HPGD  was highest  in  all  sites at the beginning of
pregnancy and  at (NT). Following  induced  parturition  HPGD was  lower after  (AP)  and  (GC) compared
with  (NT), and was similar in  RFM and DFM.  Placentomes  stained primarily  in fetal  compartments;  inter-
placentomal signals were  observed  in  endometrial glandular and luminal epithelium.  Results indicate
that  HPGD may play  a  role  during  establishment  and  termination of  gestation.
© 2016 The  Authors.  Published by  Elsevier  Inc. This is an  open access article  under  the CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1.  Background
In ruminants, prostaglandin (PG) E2 (PGE2)  and PGF2 are key
factors involved in important processes in  the  female reproduc-
tive system, including ovulation and luteolysis [1–3],  implantation
and maintenance of pregnancy [4], induction of parturition, ripen-
ing and softening of the cervix, involution of the  uterus [5,6], and
likely also in the release of  fetal membranes [7].  In cattle, cortisol,
which is synthesized and secreted by  the fetus, induces parturition
by increasing placental estrogen production, which leads to  inten-
sified production of PGF2 and thus decreasing progesterone (P4)
secretion [3,8].  Increased myometrial contractions and softening
of the birth canal parallel these events. As reviewed elsewhere in
detail [9,10], the prepartum luteolytic cascade is largely controlled
∗ Corresponding author at: Institute of Veterinary Anatomy Vetsuisse Faculty
University of Zurich Winterthurerstrasse 260, CH-8057  Zurich, Switzerland.
E-mail addresses: jessica.vonhof@uzh.ch (J. von  Hof),  nelesprekeler@gmx.de
(N. Sprekeler), gerhard.schuler@vetmed.uni-giessen.de (G. Schuler),
boosa@vetanat.uzh.ch (A. Boos), kowalewskipl@yahoo.de,
kowalewski@vetanat.uzh.ch (M.P. Kowalewski).
1 These authors contributed equally to  this work.
by  the activity of  cyclooxygenases (COX or PTGS), in particular by its
inducible form, i.e.,  COX2 (PTGS2). Prostaglandins are synthesized
from membrane-bound phospholipids via utilization of  phospho-
lipase A2-derived arachidonic acid (AA) as  a  substrate for  COX [9].
PGH2 is  the first product in  this pathway, which is  subsequently
converted to  either  PGD2, PGE2 or PGF2 due to the activity of
PGD-synthase (PGDS), PGE2-synthase (PTGES) or  PGF2-synthase
(PGFS), respectively [9].  Additionally, PGF2 can result from the
activity of 9-ketoprostaglandin reductase (9K-PGR) utilizing PGE2
for  its  synthesis, or from the  reduction of PGD2 by  11-ketoreductase
[10].
Type 1 NAD+-dependent 15-hydroxyprostaglandin dehydroge-
nase (HPGD) is the key enzyme regulating the bioavailability of
PGs. It controls their activities by catalyzing the reversible oxidation
of PGs into  the biologically inactive forms 13,14-dihydro-15-keto-
PGF2 (PGFM) and 13,14-dihydro-15-keto PGE2 (PGEM) [11,12].
There is  strong evidence that HPGD activity is maintained by P4
[13,14] and inhibited by  progesterone receptor blockers [15,16]
and glucocorticoids [17,18].  The complex regulatory mechanisms
underlying these changes remain, however, not fully  understood.
Although there are several studies on HPGD expression [19–21],
regulation [22,23] and function [12,24], its  expression and cellu-
lar localization have never been investigated comprehensively in
http://dx.doi.org/10.1016/j.prostaglandins.2016.12.003
1098-8823/© 2016 The Authors. Published by Elsevier Inc. This is  an open access article under  the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
0/).
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uterine and placentomal tissues during different stages of bovine
pregnancy. Furthermore, the potential role of HPGD in controlling
the maintenance of pregnancy and the induction of parturition in
cattle is poorly understood. In several previous studies, hormones
such as the glucocorticoid dexamethasone and the PGF2 analog
cloprostenol, as  well as compounds interfering with P4 function,
e.g., the selective progesterone-receptor (PGR) blocker aglepris-
tone, have been widely tested on the induction of parturition in
ruminants [25–28] and other species like dogs [29–31] and humans
[14,18]. Their effects on diminishing plasma P4 concentrations and,
thereby, their luteolytic potential, were investigated [28,32–35].
Additional effects of using aglepristone in  cows, besides shorten-
ing the gestation length, include lowered myometrial activity and
reduced softening of the birth canal  compared to  naturally calv-
ing cows [36]. The probability of retention of fetal membranes is
higher in cows in which parturition is  induced with hormonal med-
ication [37,38]. Dexamethasone is proven to  upregulate COX2 and
CYP17A1 (17alpha-hydroxylase-C17, 20-lyase) in the  cotyledonary
trophoblast [36],  which results in activation of the delta-5 pathway
of placental steroid biosynthesis [39]. This  leads to  decreased P4
synthesis in favor of estrogens. However, the  roles of aglepristone,
cloprostenol and dexamethasone in  regulating HPGD and, thereby,
availability of PG in  the complex preterm signal cascade in  cattle
are still not fully understood. Therefore, in order to  characterize
their  effects on maternal HPGD expression levels, and thereby the
potential involvement of HPGD in the prepartum endocrine cas-
cade in cows, preterm animals were treated with the P4 receptor
blocker aglepristone (withdrawal of both placental and luteal P4
effects), the glucocorticoid dexamethasone (mimicking the prepar-
tal increase in fetal cortisol), or the PGF2 analog cloprostenol
(induction of luteolysis). Furthermore, bovine uteri and placen-
tomes were collected from different stages of pregnancy and mRNA
expression and immunohistochemical localization of HPGD were
examined to shed new light on PG metabolism and the coordination
of pathways leading to  parturition in cattle.
2. Methods
2.1. Animals
All animal experiments were conducted in accordance with
animal welfare legislation. Details about the experimental groups
and studies, and the animal experiment permissions are  shown in
Table 1.
Study I included interplacentomal specimens and placentomes
of 35  Holstein-Friesian cows at different stages of pregnancy
(3rd to 9th months), which were collected at a  slaughterhouse
within 30 min  after slaughtering [40,41] (n  ≥ 3  animals/month of
pregnancy). The gestational age  was estimated according to fetal
crown-rump length as described elsewhere [40,41]. In  this study
tissue material was also included from spontaneously calving cows
of the university dairy herd at the Hannover School of Veteri-
nary Medicine Foundation, Hannover, Germany, which released the
secundinae within 12 h after  expulsion of the fetus (discharged fetal
membranes; DFM; n =  5).
In Study II, DFM placentomal specimens were used and the
mRNA levels of  HPDG were compared with  those expressed in
patient cows undergoing routine cesarean section at the clinic
of the  Hannover School of Veterinary Medicine Foundation, but
retaining the fetal membranes for more than 12 h  (RFM; n  = 5).
In DFM cows, placentomes were collected per vaginam within
one h  after expulsion of the fetus using an elongated effeminator
according to Richter, as modified by  Reisinger (Hauptner, Solin-
gen, Germany) [40]. In  RFM patient cows, surgeries were performed
under local anesthesia with Procaine (Isocaine, 2% solution, Selec-
tavet, Weyarn, DE), 40 ml  paravertebral and 80 ml  at  the  site of the
incision, and a single placentome was  collected per animal [41].
For Study III,  placentomal specimens were collected from ani-
mals following preterm cesarean section at day 272, and at induced
parturition and normal parturition. All  these cows were of the
Holstein-Friesian breed with a  physiological singleton pregnancy.
More specifically, as described by Shenavai et al. [32,36], elec-
tive cesarian sections were performed in  untreated cows pre-term
on day 272 (D272; n  =  3) after insemination and placentomes were
collected to  examine the clinical situation directly before the final
labor-inducing signals occur, but on  the same  day when the treated
cows  were expected to deliver their calves [32,36]. Furthermore,
pregnant cows were treated  on day 270 after artificial insemination
with 3  g (∼5 mg/kg of  body weight)  of the PGR blocker aglepristone
(AP; Alizine Virbac Bad Oldesloe, DE; n =  3;  withdrawal of placen-
tal and luteal P4 effects) in 100 ml solvent s.c.  at four  different
sites of the lower thoracic wall. The same procedure was  repeated
24 h later on the contralateral side of the thorax. The  cows treated
with glucocorticoid (GC;  n = 4; mimicking the prepartal increase
in  fetal cortisol) received 25 mg dexamethasone-21-undecanoate
(Devamed
®
; Topkim, Istanbul, TR), and the cows  treated with
prostaglandin (CP; n = 3; induction of luteolysis) received 150 g
D-cloprostenol (Dalmazin
®
; Selectavet Dr. Otto Fischer GmbH,
Weyarn-Holzolling, DE) on  day 270 after  artificial insemination
[36]. All  cows were observed every 2 h  for signs of impending labor.
Immediately after expulsion of calves, placentomes were collected
per  vaginam. Additionally, placentomes from spontaneously calv-
ing  (d280.5 ±  1.3) cows (normal term  =  NT;  n =  5) were removed per
vaginam immediately after the expulsion of healthy calves. Secun-
dinae were released in a  timely manner in  these animals [36].
2.2. Tissue  sampling and processing
As described by Boos et al. [41], for Study I at least two  randomly
selected and comparatively large placentomes and two  segments
of the  interplacentomal uterine wall including adherent allan-
tochorion were collected at the  slaughterhouse from randomly
selected cows at different stages of pregnancy. Macroscopically vis-
ible caruncles were excised with  the  adherent allantochorion and
the surrounding uterine wall. In DFM and RFM groups, only a  sin-
gle placentome was collected from each experimental or inpatient
cow. For  Study III, three to  five placentomes – but no uterine wall
segments – were collected per vaginam immediately after parturi-
tion from each cow.
As described by Sprekeler et al. [42],  for Study  I  and II  the pla-
centomes were then divided into pieces of 10 × 10 mm  and three
samples per placentome were selected for further processing as
follows: (1) uterine wall oriented tissue cube, i.e.,  placental tissue
including maternal plate and material of the placentomal stalk; (2)
allantoic sac oriented tissue cube,  i.e., placental tissue including
fetal plate material, and finally (3) tissue cube collected from the
equatorial periphery also including fetal plate and placental tissue.
The samples were embedded in  Tissue-Tek II  (Miles, Elkhart, IN,
USA) and attached onto cork lamellae, snap frozen in  liquid  nitro-
gen and stored at −80 ◦C  [42]. For  immunohistochemistry (IHC),
besides collecting the  interplacental uterine parts, the connective
fetal tissues were dissected from the placentomes directly after
collection and centrally located  cross-sections of about 5 mm in
thickness were prepared [42]. Tissue samples were then fixed in
4% neutral buffered formaldehyde for  24 h,  washed in  tap water,
dehydrated in a graded ethanol series and acetic acid-n-butyl ester,
and finally embedded in paraffin as previously described [41].
For Study III,  placentomes were placed on  ice and rinsed in  4 ◦C
cold PBS buffer, divided into cross-sections of approximately 5 mm
thickness and fixed in 4% neutral buffered formaldehyde and pro-
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Table 1
Experimental groups.
Study Description Number of cows Animal experiment permissions
I  and II 3rd–9th month of gestation
Uterine and placentomal tissues; collected  at
slaughterhouse
n  ≥  3 per month Animal experiments were  approved by the administration
of the district Hannover, and performed according to  the
German Law for the Protection of Animals (TierschG) and
the recommendations of the German Society of Laboratory
Animal Science (GV-SOLAS).
DFM: Uterine and placentomal tissues of spontaneously
calving cows with discharged fetal membranes <12 h  after
the  expulsion of the calf; samples collected within one
hour after expulsion of the calf
5
RFM: Placentomes of  spontaneously calving cows with
retained fetal membranes >12  h;  samples collected within
one hour  after expulsion of the calf
5
III  AP: Placentomes of cows, which were treated with
aglepristone (AP) on day 270 after artificial insemination.
Samples collected immediately after calving.
3 Animal experiments were  approved by the local ethical
committees on  the use of animals for research purposes  at
the  regional council (Regierungspräsidium Giessen, no.
V54-19c-20-15(l) Gi 18/14-Nr.41/2007; LAVES,
33.0-42502-04-09/1634; Ethical Committee of Uludag
University of Veterinary Medicine, No.
401/1510-26.03.2007).
CP: Placentomes of  cows treated with cloprostenol
(PGF2,  Cl)  on  day  270  after artificial insemination.
Samples collected immediately after parturition
3
GC: Placentomes of cows treated with dexamethasone
(GC) on  day  270 after artificial insemination. Samples
collected immediately after parturition
4
NT:  Placentomes of spontaneously calving cows without
medical treatment; normal term (NT)
5
D272: Placentomes of untreated cows with Cesarian
section (CS) on day 272 after  insemination. Samples
collected during CS
3
cessed further  as  described above. No frozen material was available
for this study.
2.3. RNA isolation and semi-quantitative real-time (TaqMan) PCR
Total RNA was isolated from collected placentomal and/or
uterine tissues used for Studies I and II  using TRIZOL-Reagent
(Invitrogen, Carlsbad, CA, USA) according to the  manufacturer’s
instructions. For Study III,  RNA-isolation was  performed on
formalin-fixed, paraffin-embedded (FFPE) tissue samples using
the RNeasy FFPE-Kit (Qiagen, Valencia, CA, USA) following the
manufacturer’s protocols and as previously described [43,44].  The
RNA content and quality were measured by spectrophotome-
try (NanoDrop 2000C; Thermo Fisher Scientific AG,  Reinach, CH).
DNAse treatment was accomplished with RQ1 RNAse-free DNAse
(Promega, Dübendorf, CH) following the manufacturer’s instruc-
tions in order  to  remove genomic DNA contaminants using 100 ng
(Studies I and  II) or 400 ng (Study III)  of total RNA  for  each sam-
ple. Reverse transcription was performed with the GOLD RNA PCR
Core Kit (Gene Amp, Applied Biosystems, Foster City, CA, USA) and
carried out in an Eppendorf Mastercycler (Vaudaux-Eppendorf AG,
Basel, CH) using an established running protocol (8 min  at  21 ◦C,
15 min  at  45 ◦C followed by 5 min at 99 ◦C).
Semi-quantitative real-time (TaqMan) PCR of HPGD and the two
housekeeping genes SDHA  and GAPDH [45] (for accession num-
bers and primer sequences see  Table 2) was performed using the
automated fluorometer ABI PRISM 7500 Fast Real Time PCR sys-
tem (Applied Biosystems, Rotkreuz, CH) as described previously
[40,46]. The samples were quantified in duplicate using the  Fast
Start Universal Probe Master (ROX; Roche Diagnostics Schweiz
AG) on 96-well optical plates (Applied Biosystems), with cDNA
corresponding to 100 ng or 400 ng of total RNA per sample that
was DNAse-treated and synthesized as  described above. Nega-
tive controls consisted of autoclaved water (instead of cDNA) and
the so-called RT minus controls (samples which were not reverse
transcribed). The reaction mixture of 25 l  included 12.5 l Fast-
Start Universal Probe Master (Roche Diagnostics, Mannheim, DE),
150 nM of the  forward and 150 nM of the reverse primers, 200 nM
TaqMan probe and 5 l  cDNA. Primers and 6-carboxyfluorescein
(6-FAM)- and 6-carboxytetramethyl-rhodamine (TAMRA)-labeled
probes (Table 1)  were designed with GenScript Inc. Software (Pis-
cataway, NJ,  USA) and ordered from Microsynth AG, Balgach, CH.
The  amplification reaction was conducted under the following con-
ditions: denaturation at  95 ◦C for 10 min, 40 cycles at 95 ◦C  for 15  s
and 60 ◦C for 60 s.  The two reference genes (SDHA and GAPDH)
were used  to calculate the relative gene expression of HPGD using
the comparative CT method ( CT  method) in compliance with
the manufacturer’s instructions for the ABI  7500 Fast Real-Time
PCR System as described by Kowalewski et al.  [47,48]. Accordingly,
the CT slope method was  applied to check the efficiency of the PCR
reactions that were set up to  ensure approximately 100%. The  speci-
ficity of the  selected PCR products for each gene was  confirmed by
commercial sequencing (Microsynth AG).
2.4. Immunohistochemical (IHC) analysis
For IHC localization of HPGD protein in bovine tissues, sections
of 3 m thickness were cut from formalin-fixed and paraffin-
embedded samples and mounted on SuperFrost Plus  microscope
slides (Menzel-Gläser, Braunschweig, DE). The sections were
deparaffinized in  xylol, rehydrated through a  graded ethanol
series and rinsed in  tap water as previously described [42,49].
Antigen retrieval was  performed in  10 mM citrate buffer pH  6.0
and endogenous peroxidase activity was  quenched by  0.3% H2O2
in  methanol. Subsequent to a  wash in  IHC buffer/0.3% Triton
X, (0.8 mM Na2HPO4, 1.47  mM  KH2PO4, 2.68 mM KCl, 137 mM
NaCl) pH 7.2–7.4, the slides were treated with 10% normal
goat  serum to  block non-specific binding sites. Afterwards, the
sections were incubated with polyclonal, affinity purified, custom-
made guinea pig anti-canine HPGD antibody (Eurogentec S.A.,
Seraing, BE; [49]) overnight at  4 ◦C at  a  dilution of  1:1000.  This
antibody was  designed by using the canine peptide sequence
HFQDYETTPFHAKTQ – C  – terminal  amino acids 252–266 of  the
HPGD sequence [GenBank:AFF60303] displaying 86% homology
with the bovine sequence. For negative and isotype controls, the
primary antibody was replaced by IHC buffer/0.3% Triton X,  or  by
using pre-immune guinea pig serum matching the protein con-
centration of the antiserum, respectively. On  the next day, the
sections were washed with [IHC/0.3% Triton X] and incubated with
a  biotinylated secondary goat anti-guinea pig antibody (AI-7000;
6
20 J. von  Hof et al. /  Prostaglandins & other Lipid  Mediators 128–129 (2017) 17–26
Table 2
Sequences of  primers and (TaqMan) probes.
Primer Primer sequence Accession ♯ Product length (bp)
HPGD forward 5′-GAA TCT CGA AGC AGG TGT CA-3′
HPGD reverse 5′-CCA GCT TTC CAA  AGT GGT CT-3′ NM 001034419.2 106
HPGD  probe 5′-TGA TCG GCC ACA TCG  CAC  TG-3′
SDHA forward 5′-ATG GAA GGT  CTC TGC GCT AT-3′
SDHA reverse 5′-ATG GAC CCG  TTC TTC  TAT GC-3′ NM 174178 79
SDHA  probe 5′-ACA GAG CGA TCA CAC CGC GG-3′
GAPDH forward 5′-GCG ATA CTC ACT  CTT  CTA CCT TCG A-3′
GAPDH reverse 5′-TCG TAC  CAG  GAA ATG  AGC TTG  AC-3′ NM 001034034.1 92
GAPDH probe 5′-CTG GCA TTG CCC TCA ACG ACC ACT T-3′
Vector Laboratories, Burlingame, USA) at 1:100 dilution at room
temperature for  1 h.  After repeated rinsing in IHC/0.3% Triton X,
tissue slides were treated with the streptavidin-avidin-peroxidase
Vectastain ABC kit (Vector Laboratories) to  enhance  the signals.
For final detection of signals, the Liquid DAB+ substrate kit (Dako
Schweiz AG, Baar, CH) was added and the reaction was  stopped after
approximately 10 min. The tissue sections were rinsed for 10 min  in
tap water, counterstained with  hematoxylin, dehydrated through
serial ethanol dilutions and coverslipped mechanically in  Pertex®
(RCM 2000
®
; Medite, Dietlikon, CH).
2.5. Statistics
For statistical tests the software program GraphPad Prism 5.0
(GraphPad Software Inc., San Diego, CA, USA) was used.
The datasets of semi-quantitative real-time PCR were tested
for normality using the Kolmogorov-Smirnov Test. The results  of
HPGD mRNA expression in  placentomes from Studies II  and III
were normally distributed and therefore the  datasets were tested
by a parametric one-way analysis of variance (ANOVA) followed
by  Dunn‘s multiple comparison test. The remaining datasets for
the uterine and placentomal HPGD mRNA expression during dif-
ferent stages of gestation (Study I) did not show normality, so  a
non-parametric one-way analysis of variance (Kruskal-Wallis test)
followed by Dunn’s post-test was applied. The  numerical data are
presented as the mean ± SD. In all cases p < 0.05  was  considered as
statistically significant.
3. Results
3.1. Expression of  HPGD mRNA
Study I: stages of pregnancy
HPGD expression in uterine and placentomal tissues was
investigated by  semi-quantitative real-time (TaqMan) PCR. HPGD-
specific mRNA was detected in all  preparations between the  3rd
and 9th month of  gestation and post-partum. Despite high indi-
vidual variations, in placentomes the highest mRNA expression of
HPGD was observed immediately post-partum (DFM), compared
with the 6th to 9th  month of pregnancy (p  < 0.05) (Fig.  1A).
HPGD mRNA expression in  the bovine uterine wall was  signifi-
cantly higher in the  3rd compared with the 6th month of  pregnancy
(p < 0.05) (Fig. 1B).
Study II: DFM versus RFM.
The mRNA expression of HPGD did  not differ  significantly
between the two groups (p  > 0.05) (Fig. 1C).
Study III: NT, D272, CP, AP  and GC
The treatments used  in  this study had different effects on
placentomal HPGD mRNA expression. Thus, its levels were sig-
nificantly lower in cows treated with aglepristone (AP) and
dexamethasone (GC) compared with untreated cows at normal
term (NT). Placentomes of cows during late gestation (D272)
Fig. 1.  Placentomal and uterine mRNA expression of HPGD at different stages of
gestation and at term. In  placentomes and uteri, HPGD  was  detected in all RNA
preparations between the  3rd and 9th months of pregnancy and at  term, with
changes that were time-dependent. The  highest mRNA expression was found during
establishment and termination of  gestation. Thus, (A) placental HPGD expression
during pregnancy was significantly higher immediately post  partum (DFM) com-
pared  to  month 6 till 9 of pregnancy (p <  0.05).  (B) uterine HPGD  expression during
gestation was in  the  3rd month significantly higher than in the 6th month (p <  0.05).
The  datasets showed no normality, therefore a  non-parametric one-way analysis
of  variance (Kruskal-Wallis) followed by Dunn‘s  post-test was applied. (C)  No  sig-
nificant differences were detected between cows with (DFM) or  without  (RFM)
discharged fetal  membranes (p > 0.05).  The datasets  of group DFM  and RFM were
normally distributed and one-way ANOVA was  applied  followed by  Dunn‘s multiple
comparison test. Numerical data are  presented as means ± SD.
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Fig. 2.  Placentomal expression profile of  bovine HPGD mRNA in groups NT, D272,
CP, AP  and GC. Detection of significantly lower placentomal HPGD mRNA levels
in  groups medicated with aglepristone (AP) or dexamethasone (GC) (*) compared
with  untreated cows at normal term  (NT) (**). P-values: NT: AP  =  p < 0.001; NT:
GC = p < 0.01; NT: D272 =  p  >  0.05; NT: CP =  p  > 0.05. Measured by  real-time PCR (Taq-
man). Data were normally distributed and analyzed using one-way ANOVA followed
by  Dunn‘s multiple comparison test. Numerical data are presented as the  mean ± SD.
and of cows treated with cloprostenol (CP) showed no signifi-
cant differences in HPGD mRNA expression compared to controls
(NT). In detail: NT vs.  AP = p < 0.001; NT  vs.  GC = p <  0.01; NT vs.
D272 = p > 0.05; NT vs.  CP  =  p >  0.05, Fig.  2.
3.2. Localization of HPGD protein
Placentomal tissues
In all placentomes, staining was  clearly detected in  the tro-
phoblast and the epithelium covering the maternal part of the
placentomes (caruncle), with staining intensity appearing stronger
in the trophoblast compared to the caruncular epithelium. No
considerable differences of staining were found in  relation to
the localization of HPGD within the  placentomal villous tree
(PVT; fetal side) or the caruncular crypt system (Fig. 3A, C–H). In
the trophoblast, immunostaining was present in uninucleate tro-
phoblast cells  (UNC), but not in  binucleate trophoblast cells (BNC)
(Fig. 3D–H). No staining was detected in  maternal and fetal stroma
(Fig. 3C–E). The staining intensity appeared strongest during post
partum while it seemed weaker in the  middle of pregnancy (Fig. 3A,
D, H). In all groups, the localization pattern of HPGD remained con-
stant (Fig. 3A–H). In  some of the tissue samples, nuclear staining
was detected, which was interpreted as non-specific background
staining.
Uterine tissues
HPGD immunoreactivity was  mainly localized in  the endome-
trial glandular (GE) and luminal epithelium (Fig. 4A–D). The
staining appeared weaker in the stroma and in  the myometrial
smooth muscle cells (MM  =  myometrium) (Fig.  4B). Immunostain-
ing seemed to  be more intense in  the  3rd month of gestation (Fig. 4A
and B) especially when compared to the 6th month  of  gestation
(Fig. 4C  and D) where it appeared weaker. The  localization pat-
tern remained constant throughout pregnancy and at  post partum
(Fig. 4A and D).
4. Discussion
The aim of the present study was to examine the  expres-
sion, and thereby indirectly, the potential involvement of HPGD
in the endocrine prepartum events in cattle,  and in particular
in the regulation of PGs release during bovine pregnancy and
parturition. The three different treatments intervene in differ-
ent regulatory mechanisms during the  complex signal cascade
leading to luteolysis and finally to  parturition in  cattle. Thus, dex-
amethasone imitates the birth-triggering factor  cortisol, which is
synthesized by the fetus after  maturation of  the hypothalamic-
pituitary-axis in  late pregnancy [50,51].  This, in turn, stimulates
cotyledonary uninucleate trophoblast cells (UNC) to  produce COX2,
which results in upregulation of prostaglandin synthesis [52].  Glu-
cocorticoids are  thought to  be co-responsible for induction of
CYP17A1 activity in placental cotyledons, thereby participating
in  a  prepartal switching mechanism redirecting steroid synthe-
sis  from delta-4 and delta-5 steroidogenic pathways in favor of
estrogen instead of  progesterone synthesis [39,53].  Concomitantly,
sulfonated estrogens may  be activated by increased expression of
estrogen sulphatase [54,55]. Prepartal up-regulation of estrogens
and the simultaneous decrease in progesterone lead to upregula-
tion of PG  synthesis, resulting in  increased prepartum output of
endometrial and myometrial PGF2 in  the cow [56,57].
The  competitive P4 receptor blocker aglepristone causes direct
abolition of  placental and luteal P4 effects. Cloprostenol, as  an
analog of  PGF2,  simulates the effect of  natural  endogenous
prostaglandin, which  together with oxytocin, stimulates myome-
trial  contractility and is directly involved in  luteolysis as shown, e.g.,
in cattle and sheep [58,59].  These hormonal changes finally lead  to
the onset of  parturition.
Based on the results obtained in the present study, HPGD indeed
seems to participate in these events. Thus, HPGD-specific mRNA
was detected in  all RNA preparations throughout the observa-
tion period and at normal and induced parturition, displaying
time-dependent changes, and indicating its functional role in par-
ticular during the establishment and termination of pregnancy,
when  its uterine and placental expression levels, respectively,
were the highest. By  revealing the lowest placentomal and uterine
expression levels during the mid-gestation, followed by signifi-
cantly increased mRNA  levels in placentomes at parturition, the
expression pattern of HPGD appears to  correlate negatively with
the placentomal activity of 3-hydroxysteroid dehydrogenase
(3HSD) and local placentomal concentrations of P4 showed before
[60].  This further implies its functional role during the onset of
parturition.
Similar effects were observed by others in the placenta of
rats which exhibited a decline in  placental HPGD activity until
mid-gestation, followed by its increased activity at term  [61].
Our findings showed the clearly detectable immunostaining of
HPGD protein in  the fetal  compartments of placentomes. In
agreement with other studies in  cows and sheep, for exam-
ple [20,62],  immunostaining in  placentomal trophoblast cells
was generally restricted to  the cytoplasm of UNCs, and no
expression was detected in binucleate trophoblast cells (BNC).
The  exact role of HPGD in trophoblast cells of the  placenta
and fetal membranes is still not clear, however, the co-
localization of HPGD with PG-synthesizing enzymes like COX2 and
20-hydroxysteroid dehydrogenase (20-HSD)/prostaglandin F-
synthase (PGFS/AKR1B5) in the UNCs indicates that PG metabolism
occurs mainly in the fetal components of the placenta [63,64].
With respect to uterine tissues, we  detected immunostaining of
HPGD protein mainly in epithelial cells of  the glands and the  lumi-
nal epithelium, whereas apparently weaker staining intensity was
detected in  cells of maternal stroma and smooth muscles. These
results are equivalent to findings by other  authors who  exam-
ined HPGD expression in the endometrium of cows [65]. This also
suggests that  in the bovine uterus and placenta, synthesis and
catabolism of PGs  are  located in  the same  cell compartments thus
allowing for efficient regulation of PGs activity in an autocrine
and paracrine manner. In addition, in uterine tissues of  different
species like  human and cattle, PG-synthesizing-enzymes COX2 and
PGFS/AKR1B5 were predominantly found colocalized with HPGD in
glandular epithelium and maternal stroma [10,16,65,66].
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Fig. 3. Immunolabeling of HPGD protein in bovine placentomes. Representative tissue sections are shown. Clearly visible HPGD staining was found in  uninucleate trophoblast
cells (UNC) and the adherent fetal plate (FP in A). Clearly weaker staining was  observed in the caruncular epithelium (CE). No cytoplasmic staining was detected in binucleate
trophoblast cells (BNC), maternal septum (MS) and fetal stroma (FS). (A) and (D) Group of  spontaneously calving cows with discharged fetal membranes (DFM); overview of
the  placentomal villi  tree (PVT) is  shown in (A). (B) Negative control (isotype  control; NC). (C) Group of spontaneously calving  cows  with retained fetal  membranes (RFM).
(E)  Group of  cows treated with dexamethasone (GC). (F) Group of cows with aglepristone treatment (AP). (G) Group of cows treated with cloprostenol (CP). (H) Placental
tissue collected in 6th month of gestation.
The increase of placental and uterine HPGD expression around
term may  have a local regulatory function. HPGD not only limits
the levels of each of the major PGs (i.e.,  PGE2 and PGF2), but also
controls the equilibrium between these two hormones. During par-
turition, the ratio between PGF2 and PGE2 changes [67] and HPGD
could be involved in that  mechanism. However, HPGD does not
seem, to be involved in the  etiology of fetal membrane retention in
cows,  as at least when it comes to  its  mRNA expression and pro-
tein  distribution patterns, they  did not  differ  significantly between
retained and normally released placenta.
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Fig. 4. Immunostaining of HPGD protein in  bovine uterine tissue during pregnancy. Representative tissue sections are shown. HPGD was mainly detected in  the epithelium
(GE, glandular epithelium) of  the uterine glands (UG)  and the luminal epithelium (LE). Weaker labeling was observed in the smooth muscle cells and the  endometrial stroma
(ES).  MM =  myometrium. Immunostaining appeared stronger in  the 3rd month (A, B) and weaker in  the middle of gestation (C,  D).
Furthermore, since uterine PGs are needed locally for the
establishment of  pregnancy in different species like  cattle,  sheep,
pigs and horses [67–72], the elevated expression of HPGD at the
beginning of gestation could be involved in protecting gestation
from PGs entering the maternal blood stream. The myome-
trial expression during that time may  indicate its contribution
to maintaining myometrial quiescence, protecting it from the
contractility-stimulating function of  PGs.
The aglepristone and dexamethasone treatments resulted in a
similar decrease of HPGD expression, most probably due to the
withdrawal of  P4, since the stimulating effect of progesterone
on HPGD is removed [13,14,23]. Due to the stimulation of HPGD
mRNA expression by  progesterone, HPGD was shown to  be down-
regulated by PGR blockers like aglepristone and mifepristone in
humans [15,16,73].  Similarly, in the placenta and uterus of  guinea
pigs, mifepristone invokes a significant decrease of HPGD  activ-
ity [74]. Besides being a strong competitive antagonist of PGR,
additionally, mifepristone reveals an  affinity for glucocorticoid
receptors [75,76].  The present results provide strong support that
also in cattle the HPGD up-regulating effect of P4 is  blocked by
aglepristone.
Cortisol results in  a significant down-regulation of HPGD and
leads to a potent inhibition of the PGF2 to  PGFM conversion in
primary cultures of human placental and chorionic trophoblast
cells [77]. Co-incubation with P4 was not able to reverse the
cortisol-induced inhibition of HPGD activity [77].  However, there is
evidence that regulation of HPGD expression and activity is species-
and cell type- or organ- specific. Thus, for example, HPGD activity in
fetal rat lung increases after treatment with dexamethasone from
day 20–22 of  pregnancy [78], but conversely, renal tissues of  rats
show a withdrawal of HPGD activity after  dexamethasone treat-
ment [79]. In cattle and humans [14,77],  placental glucocorticoids
appear able to  block HPGD expression. Our results showed no sig-
nificant differences in  mRNA expression of  HPGD between cows
medicated with cloprostenol (CP) compared with animals of the
control group (NT). There is  evidence, however, that 17- estradiol
increases the activity of HPGD in human placentas [80] and rat uteri
[81,82], and after PGF2-induced luteolysis a switch in the estro-
gen:progesterone ratio in  favor of estrogen is observed in cows [20].
This, together with the high prostaglandin concentration, could be
the  reason for  the high HPGD mRNA expression in  the PG group.
Clearly, the presented data obtained in  its  quantitative part  at
the  mRNA level, are not definite. The  exact  involvement of  HPGD  in
the  endocrine prepartum events in  cattle and the underlying mech-
anisms causing the withdrawal of HPGD by glucocorticoids and
aglepristone remain to be further investigated in  studies involving
higher number of animals and presenting functional approaches,
including protein expression levels  and enzyme activity studies.
5. Conclusions
In bovine placentomes and uterus, HPGD is suggested to play a
regulatory role during establishment and termination of pregnancy
and in protection of the fetus against maternal prostaglandins
and myometrial contractions. Its uterine and placental expres-
sion appears to be  time-dependent and, within the placenta, it
is localized predominantly in the fetal part. Thus, its expression
is restricted mainly to  the cytoplasm of UNCs, where it seems to
be colocalized with the PG-providing 20-HSD/AKR1B5. At  term,
HPGD withdrawal can be induced by aglepristone and the gluco-
corticoid dexamethasone. These data support the  assumption that
HPGD is a P4-dependent enzyme.
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